00:00 – Intro & welcome to Chris Burns, CEO of Amplia
02:00 – Why pancreatic cancer is so deadly & hard to diagnose
06:30 – Current treatment options: Gem/Abraxane vs FOLFIRINOX
11:20 – Side effects & challenges with chemotherapy
15:00 – Why pancreatic cancer is difficult to treat (fibrosis & mutations)
19:00 – Amplia’s approach: FAK inhibitors and how they work
23:00 – History of FAK inhibitors & Amplia’s drug development story
27:00 – ACCENT trial design and early results (response rate, PFS)
32:00 – Complete responses & long-term responders (12–18+ months)
36:00 – Next steps: Simplicity trial with FOLFIRINOX
38:30 – Path to registrational trial & FDA fast track
41:00 – Combination opportunities: KRAS inhibitors & ADCs
43:00 – Commercial strategy, pricing, partnerships
44:30 – Wrap-up & final thoughts